CysC levels were measured in sequential plasma samples from @ subjects with ADHF who were enrolled in the ASCEND-HF ( Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure ) biomarker sub-study ( randomized to nesiritide therapy vs. placebo ) , and followed for all-cause death ( @ days ) and recurrent hospital stay ( @ days ) .